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Background: Overweight and obesity, which have a substantial impact on health in the general population, have
similar prevalence in solid organ transplant recipients but carry even more serious ramifications. As this group’s use
of immunosuppressive medication increases the risk for comorbidities, e.g. metabolic syndrome and cardiovascular
disease, the prevention of additional risk factors is vital. This systematic review will be the first to summarize the
issue of weight gain, overweight and obesity concurrently within and across solid organ transplantation. The three
research questions relating to solid organ transplantation are the following: (1) What are the prevalence and
evolution of overweight and obesity from pre- to post-transplant?; (2) Which pre- and post-transplant risk factors
are associated with post-transplant weight gain, overweight or obesity? and (3) Which post-transplant patient
outcomes and comorbidities are associated with pre- and post-transplant weight gain, overweight and obesity?
Methods/Design: MEDLINE via PubMed, The Cochrane Library, Cumulative Index to Nursing and Allied Health
(CINAHL), PsycINFO and Excerpta Medica DataBase (EMBASE) will be searched for original quantitative studies in
adult liver, heart, lung or kidney transplant patients. Topics of interest will be the prevalence and evolution of
overweight and obesity over time, risk factors associated with changes in weight or body mass index (BMI),
overweight and obesity, and the relationship of weight or BMI with post-transplant outcomes and comorbidities.
Screening of titles and abstracts, full-text reading and data extraction will be divided between three researchers.
Researchers will cross-check one another’s screening decisions for random samples of studies to adhere as closely
as possible to the recommendations of The Cochrane Collaboration. For quality assessment, a purpose-adapted
19-item instrument will be used. Effect sizes will be calculated for relationships investigated in a minimum of five
studies. Random effects meta-analysis with moderator analyses will be conducted if applicable.
Discussion: This systematic review will comprehensively synthesize the existing evidence concerning weight gain,
overweight and obesity in solid organ transplantation in view of magnitude, influencing factors and associations
with patient outcomes and comorbidities. The results can fuel the development of interventions to prevent weight
gain in the solid organ transplant population.
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In recent decades, overweight and obesity have become a
global public health issue. Weight categories are often spe-
cified in terms of body mass index (BMI), i.e. the quotient
of body mass in kilograms and the square of height in
metres (kg/m2). The World Health Organization (WHO)
proposed the most commonly used classification system,
defining overweight as a BMI from 25 to 29.9 and obesity
as a BMI ≥30 [1]. In 2008, more than 1.4 billion adults
were overweight, of whom roughly 500 million were
obese, indicating that the worldwide prevalence of obesity
doubled from 1980 to 2008 [2]. This development is
underpinned by the fact, between 1990 and 2010, in terms
of worldwide ranking, “high BMI” climbed as a risk factor
for disease burden from the tenth position to the sixth [3].
In Europe, North and South America, Central Asia and
parts of Africa, “high BMI” even ranked among the top
four risk factors for disease burden, following only high
blood pressure, smoking and alcohol use [3].
In addition to the BMI-based definition cited above, the
WHO defines overweight and obesity functionally as ab-
normal or excessive fat accumulation that may impair
health [4]. Overweight and obesity are associated with in-
creased risks for all-cause mortality, cancer, non-alcoholic
fatty liver disease, hypertension, type 2 diabetes and meta-
bolic syndrome [3,5-9]. Metabolic syndrome is defined as
a cluster of three or more of the following cardiovascular
risk factors: (a) waist circumference >102 cm in men
and >88 cm in women, or BMI ≥30; (b) triglyce-
rides ≥150 mg/mL; (c) fasting glucose ≥100 mg/dL;
(d) blood pressure ≥130/85 mm Hg and (e) high-density
lipoprotein <40 mg/dL in men and <50 mg/dL in women
[10]. Associated with increased cardiovascular disease and
all-cause mortality [11], but rarely occurring in persons
with BMI values <25, metabolic syndrome is closely re-
lated to overweight and obesity [12].
Considering these relationships, the negative impact of
overweight and obesity on health may also be ex-
acerbated by existing comorbidities. However, a recent
prospective cohort study of 71,527 persons showed that,
independent of the presence of metabolic syndrome,
overweight and obesity were associated with increased
risks of myocardial infarction and ischemic heart disease
[13]. These results support the hypothesis that the stu-
died outcomes are associated directly with higher body
weight per se and are not necessarily related to meta-
bolic syndrome.
The energy balance framework and prevention of weight
gain as key concept
According to the energy balance equation, i.e. energy
storage = energy intake − energy expenditure [14], weight
gain is the result of a positive energy balance due to in-
creased energy intake or decreased energy expenditure[15]. Therefore, the most obvious causes of weight gain,
overweight and obesity are a sedentary lifestyle and a
high-calorie diet. Unfortunately, this statement over-
simplifies the complex system behind the development
of overweight and obesity. A growing body of evidence
has revealed several environmental (e.g. automation and
mechanization, cohabitation, easy access and low cost of
food), behavioural (e.g. eating large portions or high-
density food, physical inactivity, television-watching habits),
psychological (e.g. conscious control over behaviour),
biological (e.g. hormonal disturbances) and genetic factors
(e.g. polygenetic defects, monogenetic mutations) influen-
cing the balance of energy intake and expenditure [16,17].
Interrelationships between these factors further compli-
cate the underlying mechanisms [17]. However, know-
ledge of the factors influencing weight gain is crucial to
further intervention development. As stated in numerous
national reports, research to develop interventions against
weight gain is a high priority [16-19]. The argument to
favour prevention of overweight and obesity over treat-
ment is based on a physiological compensatory mecha-
nism. The reduction of energy intake by food restriction
leads to decreased body energy requirements. This is a
dynamic assimilation process which helps maintain body
functions and energy reserves during phases of shortage
[20]. Overfeeding stimulates no such compensatory chan-
ges, i.e. human biology protects us from weight reduction
but not weight gain. Therefore, the prevention of weight
gain should be easier than losing weight and maintaining
weight loss [21].
Weight gain, overweight and obesity in the transplant
population
The rising overall prevalence of obesity is mirrored in the
transplant population. For example, Leonard et al. noted
that between 1990 and 2003, the percentage of liver
transplant candidates obese at the time of transplantation
increased from 15% to 25% [22], and later, Kim et al. re-
ported that, by 2011, 34.4% of liver transplant candidates
were obese [23]. Similar developments have been shown
in kidney, heart and lung transplantation [24-26]. Ad-
ditionally, excessive (up to 10 kg) weight gain in the first
year post-transplant has been described, particularly in
liver, kidney and heart transplantation [27-29]. In liver
transplantation, for example, the prevalence of obesity
1 year post-transplant was double the pre-transplant
figure [30-32]. This alarming development has been
described in various settings (e.g. single-centre studies,
database-related reports) and countries (e.g. the USA,
Great Britain, Brazil). Immunosuppressive medication is
often cited as a risk factor for weight gain. For example,
prednisone is associated with craving sweets and increa-
sing weight, especially when dosed >5 mg/day [33]. Inte-
restingly, conflicting evidence concerning this relationship
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post-transplant weight gain, overweight and obesity have
not been part of any systematic review and thus have not
yet been outlined so far.
Weight gain, overweight and obesity are serious issues
in the solid organ transplant population as they may be
contributing factors to limited improvement in long-
term outcomes in transplantation. Indeed, while the last
20 years have seen impressive first-year graft survival in-
creases across all solid organ groups, long-term survival
has not kept pace [37], and cardiovascular events have
been reported as a leading cause of mortality after solid
organ transplantation [38-40]. This can be linked to
lifestyle-related factors as well as to the development of
new comorbidities, related to the side effects of immuno-
suppressive regimens such as hypertension, dyslipidemia
and diabetes mellitus, which are all cardiovascular risk
factors that also contribute to increased risk of post-
transplant metabolic syndrome [41-44]. A major thera-
peutic aim after solid organ transplantation is therefore to
prevent and treat any risk factors, which might increase
the occurrence of those new comorbidities. Based on the
evidence from the general population, weight gain, over-
weight and obesity must be regarded as additional risk fac-
tors for the occurrence of those new comorbidities after
transplantation. Two recent meta-analyses showed the im-
pact of obesity on patient outcomes after kidney [45] and
liver [46] transplantation. In kidney transplantation, pre-
transplant obesity, defined as BMI ≥30, was associated
with an increased risk for delayed graft function (relative
risk, 1.41; 95% confidence interval, 1.26–1.57), but not
with acute rejection. The impact of pre-transplant obesity
on patient and graft survival in this analysis seemed to be
depending on the era of transplantation, with significant
associations only in studies published before 2003, com-
pared to those published afterwards [45]. In liver trans-
plantation, neither BMI by itself nor BMI after correction
for ascites had an impact on patient survival after trans-
plantation [46]. Whereas these meta-analyses provide im-
portant insights in view of pre-transplant BMI associated
with post-transplant outcomes, the evidence base re-
garding its impact on post-transplant comorbidities as
well as the impact of post-transplant weight gain, over-
weight or obesity on patient outcomes has not yet been
summarized.
Our systematic literature review will consider all solid
organ groups concurrently using the same metho-
dological approach to identify organ-specific impacts of
weight gain, overweight and obesity on patient outcomes
and risk factors for weight gain. To summarize the evi-
dence on risk factors, we propose a model based on the
dynamic energy balance framework incorporating the
environmental, behavioural, psychological, biological and
genetic factors as well as their interrelationships and wewill expand the model with specific treatment- and dis-
ease-related factors in transplantation.
Objectives
The overall purpose of this systematic literature review
is to summarize and synthesize the evidence about
weight gain, overweight and obesity in the adult solid
organ transplant (liver, heart, lung and kidney trans-
plant) population, in view of its magnitude, influencing
factors and associations with patient outcomes. The
following research questions will guide the literature
search:
 What are the prevalence and evolution of
overweight and obesity from pre- to post-transplant
in adult solid organ transplant patients?
 Which pre- and post-transplant risk factors are
associated with post-transplant weight gain,
overweight or obesity in adult solid organ transplant
recipients?
 Which post-transplant patient outcomes and
comorbidities are associated with pre- and
post-transplant weight gain, overweight and obesity
in adult solid organ transplant recipients?
Methods/Design
This review is registered with the International Prospective
Register of Systematic Reviews (PROSPERO) under re-
gistration number CRD42014009151. The structure of
this study protocol follows the recommendations of the
Cochrane Handbook for Systematic Reviews of Interven-
tions [47].
Criteria for considering studies for review
Type of studies
Original quantitative studies, including prospective or
retrospective cohort studies, case-control studies and
cross-sectional studies, will be considered for review. Al-
though this systematic review will not specifically assess
the effectiveness of interventions, randomized controlled
trials (RCTs) with intervention and control groups will
be included and data extracted according to our inclu-
sion and exclusion criteria. Mixed methods studies will
be included if the aim of the quantitative part is suffi-
ciently described to meet our inclusion criteria.
Types of participants
Only first-time liver, heart, lung or kidney transplant
candidates or recipients aged ≥18 years will be included.
The following patients will be excluded: candidates with-
out post-transplant data collection or patients awaiting
or having received multi-organ transplantation or re-
transplantation.
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Studies should examine at least one of the following
topics:
 Changes in weight or BMI over time, either pre- to
post-transplant or post-transplant. Quantitative
studies which provide only a point prevalence of
weight and BMI as part of their sample characteristics
but no examination of relationships between weight
or BMI and associated risk factors, outcomes or
comorbidities will be excluded.
 Any pre- or post-transplant risk factors and
correlates associated with post-transplant weight
gain, overweight and obesity. Depending on the
study design (e.g. longitudinal) and statistical tests
(e.g. multivariate analysis), special attention will be
paid as to whether a factor may be regarded as a
true predictive risk factor for weight gain,
overweight and obesity. As weight gain may be the
result of multiple interrelated factors, we will
predefine neither risk factors nor correlates of
interest. For guidance, following factor categories for
both, the time before and after transplantation will
be applied in every organ group: treatment- and
disease-related, biological, genetic, environmental,
behavioural and psychological.
 The relationship of weight to any post-transplant
outcome or comorbidity. Again, specific outcomes
of interest will not be predefined as we rather aim to
compile all relevant information to describe and
discuss the current state of evidence. Relevant
outcomes will likely include patient and graft
survival, acute and late rejection, length of stay in
hospital and the intensive care unit, costs, any
post-operative, cardiovascular or pulmonary
complications, any comorbidities and quality of life.
We will also check and report whether any other
outcomes of interest have been assessed and include
these in the analysis.
Search methods for identification of studies
Information sources
The following electronic databases will be searched:
MEDLINE via PubMed, The Cochrane Library, Cumula-
tive Index to Nursing and Allied Health (CINAHL), Psy-
cINFO and Excerpta Medica DataBase (EMBASE). The
reference lists of included studies will be searched to
identify additional studies. No limits will be applied to
the search.
Search strategy
The set of search terms was developed according to the
PICOD criteria (Participants, Interventions/Exposure,
Comparisons, Outcomes/Topics, Design) and modifiedbased on an earlier scoping review (by SB) of this topic.
All terms within each PICOD concept were combined
with the Boolean operator OR, and then the PICOD
concepts were combined with the Boolean operator
AND. In order to allow a broad variety of search results
regarding risk factors, patient outcomes and comorbidi-
ties, the search strings will be restricted to two concepts:
“participants” and “exposure”. The search string for
MEDLINE was developed first and then translated for
the remaining databases. The process was discussed with
a librarian, who also checked the peculiarities of every
database and consequences for the search strategy and
the search strings. A detailed PubMed search string is
provided as follows:
((“Body Mass Index” [Mesh] OR “obesity” [Mesh] OR
“overweight” [MeSH Terms] OR “Weight Gain” [Mesh]
OR “Body Weight Changes” [Mesh:noexp] OR “Body
Weight” [Mesh:noexp]) OR (“BMI” [Text Word] OR “Body
Mass Index” [Text Word] OR “obesity” [Text Word] OR
“overweight” [Text Word] OR “weight gain” [text word]
OR “body weight change*” [Text Word] OR “body weight”
[Text Word] OR “weight” [Text Word] OR “Ideal Body
Weight” [Mesh] OR “weight management” [Text Word]
OR “body size” [Text Word]) AND (“organ transplant*”
[Text Word] OR “transplant*” [Text Word] OR “heart
transplant*” [Text Word] OR “liver transplant*” [Text
Word] OR “lung transplant*” [Text Word] OR “kidney
transplant*” [Text Word]) OR (“Kidney Transplantation”
[Mesh] OR “Lung Transplantation” [Mesh] OR “Heart
Transplantation” [Mesh] OR “Liver Transplantation”
[Mesh] OR “Organ Transplantation” [Mesh:noexp] OR
“Transplantation” [Mesh:noexp])).
Data collection and analysis
Selection of studies
The literature search will be performed by SB. The results
will be transferred to a reference manager (EndNote X5,
Thomson Reuters). Although duplicates should be ex-
cluded by merging the search results in the reference
manager library, a visual inspection will be performed to
check for any that remain. The study selection process
covers two stages: stage 1 with title and abstract screening
and stage 2 with full-text reading of potentially relevant
studies. In both stages, the total number of studies will be
divided into three equal work packages, i.e. one for each
of three researchers (SB, NI, GD). Each researcher will in-
dependently evaluate the studies in the allocated work
package against the inclusion and exclusion criteria (see
Table 1). This deviates from The Cochrane Collaboration
recommendations, which specify that at least two people
should independently select studies and then verify all re-
sults [47]. As the literature search of this systematic review
has been pilot-tested several times, with the final version
retrieving more than 13,000 hits, the proposed procedure
Table 1 Overall inclusion and exclusion criteria for stages 1 and 2
Inclusion if Exclusion if
Language • Article reported in English, German, Dutch or French Yes No
Design • Original quantitative study design: Yes No
RCT, prospective and retrospective cohort, case-control, cross-sectional, mixed methods studies
(NOT: case reports, reviews, editorials, letter to the editor, qualitative research)
Population • First and single liver, heart, lung or kidney transplant candidates or recipients Yes No
(NOT: multi-organ or re-transplant)
• Patient age ≥18 years at transplantation
Content Studies examining at least one relevant topic: Yes No
• Changes in weight or BMI over time
• Risk factors or correlates associated with weight or BMI, overweight and obesity
• Relationship of weight or BMI with any post-transplant outcome and comorbidities
(NOT: studies reporting only a point prevalence)
Access • Full-text article accessible Yes No
If a decision according to the title and abstract (stage 1) is not possible, include study for full-text reading (stage 2).
RCT randomized controlled trial, BMI body mass index.
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quality in stages 1 and 2, the three researchers will cross-
check a random sample of 5% of one another’s inclusion
and exclusion decisions. Where a question arises concern-
ing eligibility, the decision will be discussed between the
three researchers, with consensus required for inclusion of
a study in the next stage of the process. In cases of dis-
agreement, a fourth researcher (SDG) will be involved for
further discussion until consensus is reached. The study
selection process will be pilot-tested and evaluated in 50
studies for stage 1 and in 6 studies for stage 2. An Excel
spreadsheet will be used to document the reasons for
inclusion and exclusion. The selection process will be
depicted using a PRISMA flow chart.
Data extraction and management
Studies meeting the inclusion criteria in stage 2 will be
eligible for data extraction. The final set of studies will
again be divided between three researchers (SB, NI, GD),
who will then independently extract the data. An Excel
spreadsheet has been developed to systematically collect
the variables listed in Table 2. The three researchers will
check one another’s data extraction in a randomly se-
lected sample of 5% of the studies. The data extraction
procedure will be pilot-tested and evaluated in 12 stu-
dies. In cases where two or more articles examine the
same dataset, all will be used for data extraction.
Quality appraisal
For quality appraisal, we will use a 19-item instrument
specifically adapted for this systematic review. The qua-
lity assessment instrument is provided in an additional
file (see Additional file 1). Our instrument was primarily
derived from the 27-item checklist compiled by Downsand Black [48] and modified in a three-step process: (1)
As the current systematic review will not focus on the
effectiveness of treatments, the 11 questions concerning
interventions, follow-up, representativeness of parti-
cipants, blinding and randomization, more precisely, the
questions originally numbered 8, 9, 12–16, 19, 23, 24
and 27, were removed. (2) The sequence of the re-
maining 16 questions was re-arranged to better facilitate
rating. (3) Three questions from a quality assessment in-
strument used for another systematic review project (De
Geest S, Dobbels F, De Simone P, 2011: Search manual
B-SERIOUS systematic literature review, personal com-
munication) were added, which were numbered 2, 18
and 19 in our final instrument. The results of the quality
appraisal will be displayed with the Cochrane Risk of
Bias summary figure provided by Cochrane Review
Manager 5.2 [49]. The quality assessment of the studies
will be performed independently by three researchers
(SB, NI, GD). The three reviewers will randomly check
one another’s quality assessments in a random sample of
5% of the appraised studies.
Data analysis and presentation
For all aims, findings will be presented both in a narra-
tive synthesis, as well as in tables and figures. Meta-
analysis techniques will be used where relationships (i.e.
risk factors and outcomes associated with weight gain,
overweight or obesity, respectively) were investigated in
five studies or more by calculating effect sizes to analyse
the strength and direction of the relationships. If mul-
tiple studies examine the same sample for the same out-
come, the sample will only be included once in any
meta-analysis. Effect sizes will be presented as standar-
dized mean differences (d index) for outcomes analyzing
Table 2 Variables for data extraction
Variables
General information • First author, title, year, journal,
country, setting, language
Design • e.g. prospective or retrospective
cohort, RCT, case-control, cross-
sectional, mixed methods studies
• Time frame of data collection
Population • Type of transplant
• Inclusion and exclusion criteria
• Sample size
• Age, gender, race
• Disease characteristics
• Time of follow-up in years
Definitions and measurements • BMI categories
• Body composition
• Instruments and assessment tools
Statistics • Specify univariate and multivariate
analysis
Epidemiological data • Prevalence of BMI categories
• Evolution of weight or BMI
Risk factors and correlates • Treatment- and disease-related,
biological, genetic, environmental,
behavioral or psychological factors
• Time: pre- or post-transplant
Note in: numbers/frequencies, mean/
standard deviation, median/
interquartile range, odds ratio, risk
ratio, effect size, p value, others
Patient outcomes • Acute or late rejection
• Any postoperative, cardiovascular or
pulmonary complications
• Mortality, time of survival
• Length of stay in hospital/intensive
care unit
• Costs
• Quality of life
• Other outcomes as mentioned in the
article
• Any comorbidities
Note in: numbers/frequencies, mean/
standard deviation, median/
interquartile range, odds ratio, risk
ratio, effect size, p value, others
Remarks • Strength, weakness
• Other information
RCT randomized controlled trial, BMI body mass index.
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expressed as odds ratios for meta-analyses of risk factors
and comorbidities. All effect sizes will be reported with
standard errors and corresponding 95% confidence inter-
vals. Because we expect sample heterogeneity among theprimary studies, estimated effects will be pooled using a
random effects model. Heterogeneity between the in-
cluded studies will be assessed using both the Cochran
Q test, with a p value <0.1 indicating significant hetero-
geneity, and I2 statistics, with values of 25%, 50% and
75% indicating moderate low, moderate and high hete-
rogeneity, respectively [50]. Moderator analysis will be
conducted using standard meta-regression (for conti-
nuous moderators) and ANOVA (for dichotomous mode-
rators). Analyses will be conducted using Comprehensive
Meta-Analysis software (Biostat, Inc., Englewood, NJ,
USA). Study quality assessments will be analysed as mode-
rators to investigate the influence of study quality on out-
comes. Further, moderator analyses will be conducted on
patient and study characteristics (e.g. type of transplant,
sample mean age, race/ethnicity, gender, type of immuno-
suppression, publication date, geographical location) and
comorbidities.
Discussion
To the best of our knowledge, this systematic literature
review will condense and compare, for the first time, the
current state of evidence on weight gain, overweight and
obesity, their risk factors and correlates, as well as their
associated impacts on outcomes within and across all
four solid organ transplant populations. The results
should be valuable for both clinical practice and re-
search. Although all solid organ transplant recipients
seem to be susceptible to gain weight, the organ groups
may differ in view of risk factors and consequences. An
overview of the existing evidence will help healthcare
workers to adapt and integrate relevant findings into
their daily practice, to provide targeted patient education
and to support patient self-management. Additionally,
the results will add crucial evidence to expand our the-
oretical model. As a subsequent step, the identification
of risk factors and correlates associated with post-
transplant weight gain is potentially a key element for
the development of effective interventions to prevent
weight gain following solid organ transplantation. Fi-
nally, this systematic review will identify gaps in the
literature, which might be addressed in future research.
Additional file
Additional file 1: Quality assessment instrument. The 19-item quality
assessment instrument was primarily derived from the 27-item checklist
by Downs and Black [48]. The questions were re-arranged to better
facilitate rating and questions from another systematic review project
(De Geest S, Dobbels F, De Simone P, et al. 2011) were added to suit the
needs of our review.
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